Literature DB >> 25301831

Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.

Martin H Ruwald1, Scott D Solomon2, Elyse Foster2, Valentina Kutyifa2, Anne-Christine Ruwald2, Saadia Sherazi2, Scott McNitt2, Christian Jons2, Arthur J Moss2, Wojciech Zareba2.   

Abstract

BACKGROUND: Appropriate guideline criteria for use of implantable cardioverter-defibrillators (ICDs) do not take into account potential recovery of left ventricular ejection fraction (LVEF) in patients treated with CRT-defibrillator. METHODS AND
RESULTS: Patients randomized to CRT-defibrillator from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial who survived and had paired echocardiograms at enrollment and at 12 months (n=752) were included. Patients were evaluated by LVEF recovery in 3 groups (LVEF ≤35% [reference], 36%-50%, and >50%) on outcomes of ventricular tachyarrhythmias (VTAs), VTA ≥200 bpm, ICD shock, heart failure or death, and inappropriate ICD therapy by multivariable Cox models. A total of 7.3% achieved LVEF normalization (>50%). The average follow-up was 2.2±0.8 years. The risk of VTA was reduced in patients with LVEF >50% (hazard ratio [HR], 0.24; 95% confidence interval [CI], 0.07-0.82; P=0.023) and LVEF of 36% to 50% (HR, 0.44; 95% CI, 0.28-0.68; P<0.001). Among patients with LVEF >50%, only 1 patient had VTA ≥200 bpm (HR, 0.16; 95% CI, 0.02-1.51), none were shocked by the ICD, and 2 died of nonarrhythmic causes. The risk of HF or death was reduced with improvements in LVEF (LVEF >50%: HR, 0.29; 95% CI, 0.09-0.97; P=0.045; and LVEF of 36%-50%: HR, 0.44; 95% CI, 0.28-0.69; P<0.001). For inappropriate ICD therapy, no additional risk reduction for LVEF>50% was seen compared with an LVEF of 36% to 50%. A total of 6 factors were associated with LVEF normalization, and patients with all factors present (n=42) did not experience VTAs (positive predictive value, 100%).
CONCLUSIONS: Patients who achieve LVEF normalization (>50%) have very low absolute and relative risk of VTAs and a favorable clinical course within 2.2 years of follow-up. Risk of inappropriate ICD therapy is still present, and these patients could be considered for downgrade from CRT-defibrillator to CRT-pacemaker at the time of battery depletion if no VTAs have occurred. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00180271.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  arrhythmias, cardiac; cardiac resynchronization therapy; defibrillators, implantable; prognosis; ventricular dysfunction, left

Mesh:

Year:  2014        PMID: 25301831     DOI: 10.1161/CIRCULATIONAHA.114.011283

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

Review 1.  Epidemiology of "Heart Failure with Recovered Ejection Fraction": What do we do After Recovery?

Authors:  Johny S Kuttab; Michael S Kiernan; Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2015-12

Review 2.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 3.  Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure.

Authors:  Yitschak Biton; Jayson R Baman; Bronislava Polonsky
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

4.  Myocardial recovery after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.

Authors:  Norman C Wang; Aliza Hussain; Evan C Adelstein; Andrew D Althouse; Michael S Sharbaugh; Sandeep K Jain; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-09-28       Impact factor: 1.468

Review 5.  When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?

Authors:  Sana M Al-Khatib; Daniel J Friedman; Gillian D Sanders
Journal:  Card Electrophysiol Clin       Date:  2018-03

6.  Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Authors:  Anne-Christine Ruwald; Mehmet K Aktas; Martin H Ruwald; Valentina Kutyifa; Scott McNitt; Christian Jons; Suneet Mittal; Jonathan S Steinberg; James P Daubert; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-20       Impact factor: 1.468

7.  Myocardial perfusion and left ventricular quantitative parameters obtained using gated myocardial SPECT: Comparison of three software packages.

Authors:  Sotiria Alexiou; Panagiotis Georgoulias; George Angelidis; Varvara Valotassiou; Ioannis Tsougos; Dimitrios Psimadas; Velissarios Lakiotis; Agaristi Kaspiri; Dimitrios Alexopoulos; Dimitrios Apostolopoulos; Pavlos Vassilakos
Journal:  J Nucl Cardiol       Date:  2016-11-21       Impact factor: 5.952

Review 8.  Structural and Physiological Imaging to Predict the Risk of Lethal Ventricular Arrhythmias and Sudden Death.

Authors:  Saurabh Malhotra; John M Canty
Journal:  JACC Cardiovasc Imaging       Date:  2019-10

9.  Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.

Authors:  Selcuk Adabag; Kristen K Patton; Alfred E Buxton; Thomas S Rector; Kristine E Ensrud; Kairav Vakil; Wayne C Levy; Jeanne E Poole
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

Review 10.  Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.

Authors:  Amir AbdelWahab; John Sapp
Journal:  Curr Cardiol Rep       Date:  2017-09-13       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.